The tactics of treatment of sclerites of rheumatoid genesis

Inflammatory lesions of the sclera have a recurring course with a wide range of clinical manifestations and are hard to treat by medications. Purpose: to develop a combined therapy pattern with the use of medications Broxinac® (bromfenac) and Visallergol (olopatadine 0.2 %) in patients with sclerites of rheumatoid genesis. Materials and methods. 26 patients diagnosed with scleritis were divided into 2 groups. Group 1 included 12 patients (18 eyes) who received instillations of diclofenac 4 times a day. Group 2 consisted of 14 patients (19 eyes) who received instillations of bromfenac once a day and olopatadin 0.2 % once a day. All patients had a diagnosis of rheumatoid arthritis, positive HLA-B27. Results. A decline in activity of sclerites on the McCluskey scale in the course of treatment was recorded in both study groups. By the concluding 40th day of treatment, a more significant clinical effect was noted in the group receiving bromfenac andolopatadin : 0.6 points as compared to 1.4 points in group 1. After anti inflammatory treatment cessation in group 1, exacerbation of scleritis was noted in 5 cases during the 3rd to 5th week of the cessation. In contrast, group 2 showed only 1 case of exacerbation four weeks after the cessation. Conclusion. Sclerites therapy requires a long time and is associated with the development of complications in the treatment process. To increase the effectiveness of therapy of these diseases and reduce the risk of complications, modern NSAIDs with a minimum number of instillations are needed. For citation: Yani Е.V., Vakhova Е.S., Seliverstova К.Е. The tactics of treatment of sclerites of rheumatoid genesis. Russian ophthalmological journal. 2018; 11 (1): 93-7. doi: 10.21516/2072-0076-2018-11-1-93-97 (In Russian).

склерит, HLA-B27, неинфекционные заболевания, бромфенак, олопатадин 0,2%, ревматоидный артрит, scleritis, HLA-B27, non-infectious diseases, bromfenac, olopatadine 0,2%, rheumatoid arthritis

1. Goronzy J.J., Weyand C.M. Developments in the scientific understanding of rheumatoid arthritis. Arthritis research & therapy. 2009; 11: 249. https://doi.org/10.1186/ar2758

2. Akpek E.K., Thorne J.E., Qazi F.A., Do D.V., Jabs D.A. Evaluation of patients with scleritis for systemic disease. Ophthalmology. 2004; 111: 501-6.

3. Hodson K.L., Galor A., Karp C.L., et al. Epidemiology and visual outcomes in patients with infectious scleritis. Cornea. 2013; 32: 466-72. doi: 10.1097/ICO.0b013e318259c952

4. Hwang Y.S., Chen Y.F., Lai C.C., Chen H.S., Hsiao C.H. Infectious scleritis after use of immunomodulators. Archives of Оphthalmology. 2002; 120:1093-4.

5. Нероев В.В., Яни Е.В. Результаты работы по целевой программе «Ликвидация устранимой слепоты вследствие роговичной и воспалительной патологии». В кн.: Материалы VII Российского межрегионального симпозиума «Ликвидация устранимой слепоты: всемирная инициатива ВОЗ. Ликвидация устранимой слепоты вследствие роговичной и воспалительной патологии». Москва; 2015: 22-31.

6. Яни Е.В., Позднякова В.В., Селиверстова К.Е. Современные возможности терапии лекарственных офтальмоаллергозов. Российский офтальмологический журнал. 2017; 10(3): 108-12.

7. McCluskey P., Wakefield D. Prediction of response to treatment in patients with scleritis using a standardised scoring system. Austr. and New Zealand Journ. of Ophthalmol. 1991; 19(3):211-5.